Journal Mobile Options
Table of Contents
Vol. 3, No. 3, 2006
Issue release date: September 2006
Neurodegenerative Dis 2006;3:129–133

Genetic Variability in CHMP2B and Frontotemporal Dementia

Momeni P. · Rogaeva E. · van Deerlin V. · Yuan W. · Grafman J. · Tierney M. · Huey E. · Bell J. · Morris C.M. · Kalaria R.N. · van Rensburg S.J. · Niehaus D. · Potocnik F. · Kawarai T. · Salehi-Rad S. · Sato C. · St. George-Hyslop P. · Hardy J.
aLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Md., USA; bCentre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada; cCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pa., dCognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md., USA; eInstitute for Health and Ageing, Newcastle General Hospital, fHealth Protection Agency, Chemical Hazards and Poisons Division, Wolfson Unit of Chemical Pharmacology, Newcastle upon Tyne, UK; gDepartment of Psychiatry, University of Stellenbosch, Tygerberg, South Africa

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


A nonsense/protein chain-terminating mutation in the CHMP2B gene has recently been reported as a cause of frontotemporal dementia (FTD) in the single large family known to show linkage to chromosome 3. Screening for mutations in this gene in a large series of FTD families and individual patients led to the identification of a protein-truncating mutation in 2 unaffected members of an Afrikaner family with FTD, but not in their affected relatives. The putative pathogenicity of CHMP2B mutations for dementia is discussed.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Morris HR, Khan MN, Janssen JC, et al: The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 2001;58:1813–1816.
  2. Rademakers R, Cruts M, van Broeckhoven C: The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 2004;24:277–295.
  3. Houlden H, Baker M, Adamson J, et al: Frequency of tau mutations in three series of non-Alzheimer’s degenerative dementia. Ann Neurol 1999;46:243–248.
  4. Gydesen S, Hagen S, Klinken L, Abelskov J, Sorensen SA: Neuropsychiatric studies in a family with presenile dementia different from Alzheimer and Pick disease. Acta Psychiatr Scand 1987;76:276–284.
  5. Brown J, Ashworth A, Gydesen S, et al: Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 1995;4:1625–1628.
  6. Yancopoulou D, Crowther RA, Chakrabarti L, Gydesen S, Brown JM, Spillantini MG: Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). J Neuropathol Exp Neurol 2003;62:878–882.
  7. Skibinski G, Parkinson NJ, Brown JM, et al: Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37:806–808.
  8. Vidal R, Frangione B, Rostagno A, et al: A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999;399:776–781.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50